New combo therapy aims to slow advanced prostate cancer

NCT ID NCT04704505

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a special hormone therapy (bipolar androgen therapy) to a targeted radiation drug (radium-223) can slow the growth of prostate cancer that has spread to bones and stopped responding to standard hormone treatments. About 47 men with this advanced cancer will receive both treatments every 28 days for up to 6 cycles. The goal is to see how long the cancer stays under control and to monitor side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT METASTATIC PROSTATE ADENOCARCINOMA PROSTATE ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Amber Michalik
RECRUITING

Baltimore, Maryland, 20707, United States
Moinhos de Vento Hospital
NOT_YET_RECRUITING

Porto Alegre, 90560-010, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.